成長差別化因子15 (GDF15) の多面的な役割:がんカケキシアから標的治療へのナラティブレビュー
PubMedで要約を見る
まとめ
この要約は機械生成です。成長差別化因子15 (GDF15) は,多くの固体腫瘍の不良予後に関連した主要な腫瘍学バイオマーカーです. GDF15を標的とした治療は,特に頭頸部がんにおいて,がんカシェキアを改善し,免疫反応を強化することを約束しています.
科学分野
- 腫瘍学
- 分子生物学
- 癌 研究
背景
- 成長差別化因子15 (GDF15) は,腫瘍学における新興のバイオマーカーおよび治療標的である.
- GDF15濃度の上昇は,大腸,胃,臓,乳がん,肺がん,前立腺がん,頭頸がんを含む様々な固体腫瘍の予後が悪いことと相関しています.
- GDF15はPI3K/ AKT,MAPK/ ERK,SMAD2/3のシグナル伝達によって腫瘍の進行に影響を与え,転移,免疫回避,および化学抵抗を促進する.
研究 の 目的
- 固体腫瘍におけるGDF15の役割に関する文献をレビューする.
- 頭頸部がんにおける GDF15の役割を強調する.
- GDF15-GFRAL軸を標的とした治療戦略を探求する.
主な方法
- 物語の文献レビュー
- 固体腫瘍,特に頭頸部状細胞癌 (HNSCC) のGDF15に注目する.
- GDF15-GFRAL軸の治療標的の分析
主要な成果
- HNSCCにおけるGDF15過剰発現は,攻撃的なフェノタイプ,放射線抵抗,化学療法および免疫チェックポイント阻害剤 (ICI) に対する弱い反応と関連しています.
- GDF15は結腸直腸がん,臓がん,前立腺がんの転移と治療抵抗に寄与する.
- GDF15- GFRAL軸の治療ターゲティングは有望であった:ポンセグロマブはカケキシアのアウトカムを改善し,ニヴォルマブと併用したビズグロマブはICI耐性腫瘍における免疫反応を強化した.
結論
- 悪性腫瘍におけるGDF15の役割を完全に理解するには,さらなる研究が必要である.
- GDF15を標的とする治療の患者選択を 精査することは極めて重要です
- 既存のがん治療法との組み合わせによるアプローチの評価は正当化されています.
関連する概念動画
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

